IPV Vaccines Market Synopsis

IPV Vaccines Market Size is Valued at USD 183.96 Million in 2023 and is Projected to Reach USD 383.35 Million by 2032, Growing at a CAGR of 8.50% From 2024-2032.

The IPV (Inactivated Poliovirus) Vaccines Market pertains to the global manufacture, distribution and supply of vaccines that are comprised from a weakened inactivated poliovirus and are administered with the purpose of providing immunization to poliomyelitis. While the OPV still developed from a live virus that could cause polio, IPV vaccines contain killed virus meaning that they are safe for immunocompromised persons. They are usually in the form of injection and they form part of efforts being made around the world to eliminate poliomyelitis and their demand emanates from governmental immunization programs, health care facilities and public health organizations.

• Currently, IPV vaccines have received significant attention from global health agencies steering towards polio eradication. Today, many global organizations such as WHO, UNICEF, and GPEI, have invested significant efforts to’ halt poliovirus spread. These campaigns highlights the contribution of IPV in those countries where OPV is stopped partly because of the potential for vaccine derived poliovirus. With the improvement of immunization schedules in a country, the requirement of IPV grows especially in the area, which have shifted from OPV to IPV.
• The other influencing factor is the effect due to the increase in basic healthcare knowledge and the state government campaign on the use of vaccination. With enhanced development in the health sectors of developing countries, vaccination is enhanced hence the increased need for the IPV vaccines. Further, the efforts that are being conducted to undertake research on IPV formulations capable of offering fewer doses but with high efficacy as key drivers to the adoption of IPV. This has also supported market investment from public and private sector, which has been complementing the general market growth.

IPV Vaccines Market Trend Analysis

The increasing integration of IPV into combination vaccines.

• Another important characteristic of the IPV vaccines’ market is that IPV is becoming a component of combination vaccines more and more often. This innovation contributes to immunization schedules by an aggregated multiple number of vaccines in on shot thereby closing the number of times visitors to healthcare centers. It also enhances compliance rates because parents will not need to honor so many appointments concerning their children’s immunization. This is in line with the global concern on efficiency and how vaccination can be made to be more effective and available in the developing world most of the time.
• The other development is increasing concern on the transport and storage of vaccines, that is, the cold chain. The viability of IPV vaccines before and during transportation is essential to considering for immunization programs. Therefore, a large amount of money has been spent on changing cold chain infrastructure, which is crucial to the effectiveness of the vaccine as well as the in the access to them in rural or places with poor access.

Increasing awareness about the importance of vaccinations

• Thus, the mysterious of IPV vaccines offer a sizeable opportunity in the growth markets, mainly in Africa as well as Asia, where coverage deficiency still prevails. Promoting understanding of the necessity of vaccinations – which is facilitated by international aid and local government actions – has created vast opportunities for market development. There is a lot of potential for companies that can provide both cost effective and easily accessible IPV vaccines to these regions. Additionally, projects between local administrations and vaccine producers allow for the simplification of delivery and massive vaccination.
• Also, current and future improvements in vaccinations present possibilities for new IPV forms which may enhance immunogenicity or minimize the need for boosters. Establishments that invest more on research and development in this segment can devise vaccines cheaper, necessitating fewer injections, which will be helpful more so in a limited resource environment. Finally, removing the cold chain requirements for storage of vaccines through innovations with sub zero hold on vaccines might significantly change the distribution of vaccines in regions which lack proper infrastructure.

IPV Vaccines Market Segment Analysis:

IPV Vaccines Market Segmented on the basis of Vaccine type, Dosage Type, Age Group, and end-users.

By Vaccine Type, Conventional IPV segment is expected to dominate the market during the forecast period

• The IPV Vaccines Market can be segmented by vaccine type into two categories: In this study, two forms of IPV are defined, which are conventional IPV and enhanced IPV. Practical IPV is the traditional inactivated poliovirus vaccine that is applicable in the immunization programs across the world. On the same note, Improved IPV is an améliorer. contribution which is an enhanced one intended to create a better immunity or fewer doses that make it efficient in some immunization programs. Both are important in the eradication of polio with enhanced IPV emerging as the new-world option owing to its flexible dosing regimen and improved efficacy.

By age Group, Infants segment held the largest share in 2024

• The IPV Vaccines Market is segmented by age group: infant, child, and adult. Children are the most targeted group in polio immunization because they are the most susceptible to affectation by the virus and require immunization to develop adequate safeguards. Another important target audience includes children, or rather attendees aged up to five years old since they often require repeated doses for extended immunization. Generally polio impacts younger people; but in some circumstances adults also preferred IPV vaccinations for instance; travelers to polio-endemic areas and healthcare workers.

IPV Vaccines Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• North America leads this market and especially the United States due to the availability of sophisticated healthcare services and strong Immunization programs. The polio vaccination has been required for all children by the CDC which has led to ensuring there is continuous demand for IPV vaccines. Further, the key vaccine manufacturers functioning across the global market are based in the region; the companies operating in the U.S. benefit from advanced technological framework and sound supply chain networks essential to addressing regional as well as global demand.
• The region also enjoys massive proportions in research and development, leading to production of sulfomer next generation vaccines. Advanced regulatory systems in North American region along with increased health care spending ploughs ensure that good quality vaccines are developed and made available to the people. This has placed North America at the fore front of polio control and has maintained the region IS the cutting edge of the IPV vaccines market.

Active Key Players in the IPV Vaccines Market

• Sanofi (France)
• GlaxoSmithKline plc (United Kingdom)
• Merck & Co., Inc. (United States)
• Pfizer Inc. (United States)
• Serum Institute of India Pvt. Ltd. (India)
• Panacea Biotec (India)
• Bilthoven Biologicals (Netherlands)
• China National Pharmaceutical Group Corporation (China)
• Bio Farma (Indonesia)
• Astellas Pharma Inc. (Japan)
• Others

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: IPV Vaccines Market by Vaccine Type
 4.1 IPV Vaccines Market Snapshot and Growth Engine
 4.2 IPV Vaccines Market Overview
 4.3 Conventional IPV
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Conventional IPV: Geographic Segmentation Analysis
 4.4 Enhanced IPV
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Enhanced IPV: Geographic Segmentation Analysis

Chapter 5: IPV Vaccines Market by Dosage Form
 5.1 IPV Vaccines Market Snapshot and Growth Engine
 5.2 IPV Vaccines Market Overview
 5.3 Single-dose Vials
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Single-dose Vials: Geographic Segmentation Analysis
 5.4 Multi-dose Vials
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Multi-dose Vials: Geographic Segmentation Analysis

Chapter 6: IPV Vaccines Market by Age Group
 6.1 IPV Vaccines Market Snapshot and Growth Engine
 6.2 IPV Vaccines Market Overview
 6.3 Infants
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Infants: Geographic Segmentation Analysis
 6.4 Children
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Children: Geographic Segmentation Analysis
 6.5 Adults
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Adults: Geographic Segmentation Analysis

Chapter 7: IPV Vaccines Market by End-User
 7.1 IPV Vaccines Market Snapshot and Growth Engine
 7.2 IPV Vaccines Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Clinics
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Clinics: Geographic Segmentation Analysis
 7.5 Public Health Agencies
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Public Health Agencies: Geographic Segmentation Analysis
 7.6 Vaccination Centers
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Vaccination Centers: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 IPV Vaccines Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 SANOFI (FRANCE)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 GLAXOSMITHKLINE PLC (UNITED KINGDOM)
 8.4 MERCK & CO INC (UNITED STATES)
 8.5 PFIZER INC (UNITED STATES)
 8.6 SERUM INSTITUTE OF INDIA PVT LTD (INDIA)
 8.7 PANACEA BIOTEC (INDIA)
 8.8 BILTHOVEN BIOLOGICALS (NETHERLANDS)
 8.9 CHINA NATIONAL PHARMACEUTICAL GROUP CORPORATION (CHINA)
 8.10 BIO FARMA (INDONESIA)
 8.11 ASTELLAS PHARMA INC (JAPAN)
 8.12 OTHERS

Chapter 9: Global IPV Vaccines Market By Region
 9.1 Overview
 9.2. North America IPV Vaccines Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Vaccine Type
  9.2.4.1 Conventional IPV
  9.2.4.2 Enhanced IPV
  9.2.5 Historic and Forecasted Market Size By Dosage Form
  9.2.5.1 Single-dose Vials
  9.2.5.2 Multi-dose Vials
  9.2.6 Historic and Forecasted Market Size By Age Group
  9.2.6.1 Infants
  9.2.6.2 Children
  9.2.6.3 Adults
  9.2.7 Historic and Forecasted Market Size By End-User
  9.2.7.1 Hospitals
  9.2.7.2 Clinics
  9.2.7.3 Public Health Agencies
  9.2.7.4 Vaccination Centers
  9.2.8 Historic and Forecast Market Size by Country
  9.2.8.1 US
  9.2.8.2 Canada
  9.2.8.3 Mexico
 9.3. Eastern Europe IPV Vaccines Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Vaccine Type
  9.3.4.1 Conventional IPV
  9.3.4.2 Enhanced IPV
  9.3.5 Historic and Forecasted Market Size By Dosage Form
  9.3.5.1 Single-dose Vials
  9.3.5.2 Multi-dose Vials
  9.3.6 Historic and Forecasted Market Size By Age Group
  9.3.6.1 Infants
  9.3.6.2 Children
  9.3.6.3 Adults
  9.3.7 Historic and Forecasted Market Size By End-User
  9.3.7.1 Hospitals
  9.3.7.2 Clinics
  9.3.7.3 Public Health Agencies
  9.3.7.4 Vaccination Centers
  9.3.8 Historic and Forecast Market Size by Country
  9.3.8.1 Bulgaria
  9.3.8.2 The Czech Republic
  9.3.8.3 Hungary
  9.3.8.4 Poland
  9.3.8.5 Romania
  9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe IPV Vaccines Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Vaccine Type
  9.4.4.1 Conventional IPV
  9.4.4.2 Enhanced IPV
  9.4.5 Historic and Forecasted Market Size By Dosage Form
  9.4.5.1 Single-dose Vials
  9.4.5.2 Multi-dose Vials
  9.4.6 Historic and Forecasted Market Size By Age Group
  9.4.6.1 Infants
  9.4.6.2 Children
  9.4.6.3 Adults
  9.4.7 Historic and Forecasted Market Size By End-User
  9.4.7.1 Hospitals
  9.4.7.2 Clinics
  9.4.7.3 Public Health Agencies
  9.4.7.4 Vaccination Centers
  9.4.8 Historic and Forecast Market Size by Country
  9.4.8.1 Germany
  9.4.8.2 UK
  9.4.8.3 France
  9.4.8.4 Netherlands
  9.4.8.5 Italy
  9.4.8.6 Russia
  9.4.8.7 Spain
  9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific IPV Vaccines Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Vaccine Type
  9.5.4.1 Conventional IPV
  9.5.4.2 Enhanced IPV
  9.5.5 Historic and Forecasted Market Size By Dosage Form
  9.5.5.1 Single-dose Vials
  9.5.5.2 Multi-dose Vials
  9.5.6 Historic and Forecasted Market Size By Age Group
  9.5.6.1 Infants
  9.5.6.2 Children
  9.5.6.3 Adults
  9.5.7 Historic and Forecasted Market Size By End-User
  9.5.7.1 Hospitals
  9.5.7.2 Clinics
  9.5.7.3 Public Health Agencies
  9.5.7.4 Vaccination Centers
  9.5.8 Historic and Forecast Market Size by Country
  9.5.8.1 China
  9.5.8.2 India
  9.5.8.3 Japan
  9.5.8.4 South Korea
  9.5.8.5 Malaysia
  9.5.8.6 Thailand
  9.5.8.7 Vietnam
  9.5.8.8 The Philippines
  9.5.8.9 Australia
  9.5.8.10 New Zealand
  9.5.8.11 Rest of APAC
 9.6. Middle East & Africa IPV Vaccines Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Vaccine Type
  9.6.4.1 Conventional IPV
  9.6.4.2 Enhanced IPV
  9.6.5 Historic and Forecasted Market Size By Dosage Form
  9.6.5.1 Single-dose Vials
  9.6.5.2 Multi-dose Vials
  9.6.6 Historic and Forecasted Market Size By Age Group
  9.6.6.1 Infants
  9.6.6.2 Children
  9.6.6.3 Adults
  9.6.7 Historic and Forecasted Market Size By End-User
  9.6.7.1 Hospitals
  9.6.7.2 Clinics
  9.6.7.3 Public Health Agencies
  9.6.7.4 Vaccination Centers
  9.6.8 Historic and Forecast Market Size by Country
  9.6.8.1 Turkey
  9.6.8.2 Bahrain
  9.6.8.3 Kuwait
  9.6.8.4 Saudi Arabia
  9.6.8.5 Qatar
  9.6.8.6 UAE
  9.6.8.7 Israel
  9.6.8.8 South Africa
 9.7. South America IPV Vaccines Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Vaccine Type
  9.7.4.1 Conventional IPV
  9.7.4.2 Enhanced IPV
  9.7.5 Historic and Forecasted Market Size By Dosage Form
  9.7.5.1 Single-dose Vials
  9.7.5.2 Multi-dose Vials
  9.7.6 Historic and Forecasted Market Size By Age Group
  9.7.6.1 Infants
  9.7.6.2 Children
  9.7.6.3 Adults
  9.7.7 Historic and Forecasted Market Size By End-User
  9.7.7.1 Hospitals
  9.7.7.2 Clinics
  9.7.7.3 Public Health Agencies
  9.7.7.4 Vaccination Centers
  9.7.8 Historic and Forecast Market Size by Country
  9.7.8.1 Brazil
  9.7.8.2 Argentina
  9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research